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Abstract
 
The stimulation of interferon (IFN)-
 
 
 
 by interleukin (IL)-12 has been shown to provide pro-
 
tection from intracellular pathogens such as 
 
Listeria monocytogenes
 
. Tumor necrosis factor
(TNF) is also a major player in the resolution of 
 
Listeria
 
 infections and is suggested to have
more global effects than can be explained by the induction of IFN-
 
 
 
 alone. Since IL-18 syner-
gizes with IL-12 to induce IFN-
 
 
 
 production by natural killer and T helper (Th)1 cells, we
determined its role in responses to 
 
Listeria
 
. IL-18 appeared to be even more potent than either
IL-12 or IFN-
 
 
 
 for protection against this pathogen and IL-18 enhanced bacterial clearance in
 
the complete absence of IFN-
 
 
 
. Indeed IL-18 was comparable to TNF in its ability to resolve
the infection and showed a lowered protective capacity in the absence of TNF. Moreover, IL-18
 
induced macrophages to secrete both TNF and nitric oxide after a 
 
Listeria 
 
infection. IL-18 was
 
also essential for optimal IFN-
 
 
 
 production by antigen-specific T cells. Therefore, IL-18 oper-
ates via its effects on both the innate immune response, including macrophages, as well as on
Th1 cells, to protect against 
 
Listeria
 
.
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Introduction
 
Listeria monocytogenes
 
 (
 
Listeria)
 
, a gram-positive facultative
intracellular bacterium, is associated with severe infections
in newborns, the elderly, and immunocompromised indi-
viduals (1–5). Murine models of listeriosis have been exten-
sively studied to facilitate an understanding of the host im-
mune response (6, 7). Results of these studies demonstrated
that there is coordinate activation of the innate immune re-
sponse, including neutrophils, macrophages, and NK cells
(8, 9), together with the adaptive immune response of
 
CD4
 
 
 
 Th1 and CD8
 
 
 
 T cells (6, 10). Moreover, it has
been clearly demonstrated that for resolution and immunity
to develop to 
 
Listeria
 
 the induction of antigen-specific T
cells is essential (2, 10–12).
 
The release of proinflammatory cytokines from these var-
ious cell subsets was found to be pivotal in controlling pri-
 
mary immune responses to 
 
Listeria
 
. IFN-
 
 
 
, produced by
NK and T cells, clears 
 
Listeria
 
 predominantly by enhancing
the antimicrobial and antigen-presenting properties of mac-
rophages (13–15). The key macrophage product, IL-12,
provides protection from 
 
Listeria
 
 by inducing IFN-
 
 
 
 pro-
duction (16). Likewise, TNF plays a role in the clearance of
 
Listeria
 
 due in part to its induction of IFN-
 
 
 
 production (17,
18). However, IFN-
 
 
 
 does not completely replace the abil-
ity of TNF to resolve 
 
Listeria 
 
infections (16), in keeping
with observations that TNF appears to be more dominant
than IL-12 in eliciting protective primary immune responses
to 
 
Listeria 
 
(16) yet plays a lesser role than IL-12 in invoking
IFN-
 
 
 
 production by Th1 cells (19, 20). The role of these
proinflammatory cytokines in the eradication of 
 
Listeria
 
 has
 
also been confirmed in IFN-
 
 
 
 
 
/
 
  
 
(21), IFN-
 
 
 
 receptor
 
 
 
/
 
 
 
(22), IL-12
 
 
 
/
 
 
 
 (23), and TNF receptor 1
 
 
 
/
 
 
 
 (24, 25) mice.
In contrast to a primary immune response, the secondary
immune response to 
 
Listeria
 
 is more rapidly induced and is
able to overcome a high, normally lethal, dose of bacteria
(6). This acquired resistance is largely attributable to mem-
 
ory effector CD4
 
 
 
 and CD8
 
 
 
 T cells, in part by IFN-
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production (26–28). Although IL-12 is also produced in a
secondary challenge with this organism, it offers less pro-
tection than in primary responses and cannot completely
account for the effects of IFN-
 
 
 
 (28), indicating that there
may be other players involved in IFN-
 
 
 
 production at this
stage. TNF is clearly protective in secondary responses to
 
Listeria
 
, and this cytokine may complement the role of
IFN-
 
 
 
 in the bacterial clearance (27, 29). In addition to the
role of CD4
 
 
 
 and CD8
 
 
 
 T cells in the memory response to
 
Listeria
 
, the innate immune response is also essential with
neutrophils playing a critical role (30, 31).
A potentially important player in the eradication of a
 
Listeria
 
 infection is IL-18 (32), which was originally shown
to induce IFN-
 
 
 
 production in mice injected with heat-
killed 
 
Propionibacterium acnes
 
 (
 
P. acnes
 
) and LPS (32, 33). In
vitro
 
 
 
studies have since shown that IL-18 synergizes with
IL-12 to induce IFN-
 
 
 
 from differentiating and committed
CD4
 
 
 
 Th1, but not Th2, cells (34) as well as from NK cells
(35). These two cytokines can also synergize in vivo since
IL-12
 
 
 
/
 
 
 
IL-18
 
 
 
/
 
 
 
 mice displayed more profound impair-
ment of IFN-
 
 
 
 production after injection with 
 
Mycobacte-
rium bovis 
 
than did either IL-12
 
 
 
/
 
 
 
 or IL-18
 
 
 
/
 
 
 
 mice indi-
vidually (36). In addition to its IFN-
 
 
 
–enhancing capacity,
IL-18 can also augment the cytotoxic activity of both NK
and T cells (36–40) and can enhance their production of
other proinflammatory mediators (33, 36, 41–43). More-
over, studies of acute bacterial, fungal, parasitic, and viral
infections have shown a role for IL-18 in the eradication of
intracellular pathogens (44–49). However, a role for IL-18
in memory effector responses to such pathogens has not
been investigated yet, nor has its ability to protect through
mediators other than IFN-
 
 
 
.
Responsiveness to IL-18 is conferred by binding to its
cognate receptor, which consists of an IL-1R5/IL-1R7
heterodimer (50–52). Herein, using a neutralizing mAb to
the IL-1R7 chain (anti–IL-18R; reference 53) we report
an important and partly IFN-
 
 
 
–independent role for IL-18
in both innate and adaptive immune responses to 
 
Listeria
 
involving the production of TNF and nitric oxide (NO) as
well as IFN-
 
 
 
.
 
Materials and Methods
 
Mice.
 
Female Balb/c and C.B-17 severe combined immuno-
deficient (SCID) mice (both H-2d) were purchased from
Taconic Farms. Female Balb/c IFN-
 
 
 
–deficient mice (H-2
 
d
 
)
were provided by Bob Coffman (DNAX Research Institute, Palo
Alto, CA). Female mice transgenic for the DO11.10 
 
  
 
 TCR
(54) on a Balb/c genetic background were identified at age 4–6
wk by staining peripheral blood leukocytes with the anti-TCR
clonotype-specific mAb KJ1-26 (55); these mice were heterozy-
gous for the TCR-
 
 
 
 and -
 
 
 
 transgenes. All mice were housed
under specific pathogen-free conditions and were used at the age
of 6–8 wk.
 
Bacteria and Bacterial Antigens. Listeria
 
 (provided by H. Rog-
ers, K. Murphy, and E. Unanue) has been maintained in a virulent
state by repeated passage in mice. Bacteria were grown in BHI
broth (Difco) to midlog phase as determined by OD
 
560
 
 measure-
ments and aliquots were stored in 20% glycerol/PBS at –80
 
 
 
C.
 
Heat-killed 
 
Listeria monocytogenes
 
 (HKLM)
 
*
 
 was obtained by
incubating live bacteria at 74
 
 
 
C for 120 min. Aliquots were
stored at 
 
 
 
80
 
 
 
C.
 
mAbs, Cytokines, and Reagents.
 
The mAbs anti-
 
 
 
 galactosi-
dase (isotype control: GL117), anti–IL-12 (C17.8.20), anti–IL-
18R (TC30-28E3), and anti-TNF (XT22) were administered (1
mg) intraperitoneally to mice 1 h before infection with 
 
Listeria
 
and at the additional times as indicated. Recombinant mouse
cytokines were IL-2 (DNAX), TNF (Genzyme), IL-12 (BD
PharMingen), and IL-18 (PeproTech). LPS was obtained from
Sigma-Aldrich and azide-free, low endotoxin anti-CD3
 
 
 
 was ob-
tained from BD PharMingen. The antigenic peptide from
chicken OVA (OVA
 
323–339) was synthesized on an Applied Bio-
systems model 430 peptide synthesizer.
Infection with Listeria. An initial infection with Listeria was
performed by intravenous injection of 1–2   103 CFU viable
bacteria diluted in a volume of 0.2 ml PBS. For a second infec-
tion, mice were injected with 5   104 CFU viable bacteria on
day 28 after the initial infection. Actual numbers of bacteria in-
jected were determined by plating aliquots of relevant dilutions
on BHI agar (Difco). Bacterial growth in the spleen was deter-
mined on the indicated days after infection by plating relevant di-
lutions of the spleen homogenates on BHI agar. Colonies were
counted after 24 h of incubation at 37 C. LD50 were calculated
as described previously (56).
Cell Culture Ex Vivo. On the indicated day after infection,
single cell spleen suspensions were prepared from individual mice
in culture medium: RPMI 1640 medium (Bio-Whittaker) sup-
plemented with 10% FCS (UT; Hyclone Laboratories), 1 mM
L-glutamine, 10 mM Hepes, 100 U/ml penicillin, 100  g/ml strep-
tomycin, 1 mM sodium pyruvate, and 0.05 mM  -2 mercapto-
ethanol (all GIBCO BRL). Cells were incubated in 96-well plates
at a density of 106 cells per well with 3.9   104 CFU HKLM for
48 h at 37 C. Supernatants were harvested at the end of culture
and stored at  80 C until analyzed for cytokine content.
T Cell Culture In Vitro. CD4  T cells were enriched from
DO11.10 spleen cell preparations by negative selection using
magnetic-activated cell sorting with a mixture of biotinylated
anti-CD8 , anti–I-Ad, anti-B220, anti-GR1, and anti–Mac-1
mAbs (Miltenyi Biotec). The enriched cells were then purified
further using a FACStarPlus™ flow cytometer (Becton Dickin-
son) to achieve  99% CD4  T cells, demonstrated to be naive
on the basis of bright L-selectin staining (57).
Primary stimulations of these sorted CD4  T cells (2.5   105
cells per well) were conducted using 0.6  M OVA323–339, 3.9  
104 CFU HKLM, and RBC-lysed Balb/c spleen cells (5   106
cells per well; 3,000 rad) as APCs with or without the addition of
10  g/ml of the anticytokine mAbs described above (all at 10
 g/ml). T cells were expanded threefold into fresh culture me-
dium at 72 h and cells harvested on day 7 were washed three
times, counted, and restimulated with fresh APCs, OVA plus or
minus HKLM with or without the addition of anticytokine
mAbs as detailed in the individual figure legends. All concentra-
tions used for restimulation were the same as those described for
priming. Supernatants were collected at 48 h and stored at
 80 C until analyzed for cytokine content.
Macrophage Cultures In Vitro. Macrophages from peritoneal
exudates were selected by retaining adherent cells. After over-
night culture in medium at 2   106 cells per milliliter in flat-bot-
tomed 96-well plates, adherent or whole peritoneal cell popula-
tions were placed in the presence of IL-18 (100 ng/ml) or
*Abbreviation used in this paper: HKLM, heat-killed Listeria monocytogenes.345 Neighbors et al.
HKLM (3.9   104 CFUs) with or without anti–IL-18R (10  g/
ml) for 48 h, and supernatants were stored at  20 C until assayed
for cytokine content. For intracellular cytokine staining, identical
cultures were stimulated in the presence of 10  g/ml Brefeldin A
(Sigma-Aldrich) for 4 h.
Alternatively, whole peritoneal cell populations were incu-
bated at 105 cells per milliliter in flat-bottomed 96-well plates
with HKLM (3.9   104 CFUs) for 16 h and 50  l of supernatant
measured for nitrite content using 50  l Greiss reagent (3% phos-
phoric acid, 1% p-amino-benzene-sulfonamide, and 1% n-1-nap-
thylethylenediamide; Sigma-Aldrich) (58) and absorbance was
read at 540 nm.
Cytokine Assays. IFN-  was detected using a two-site sand-
wich ELISA as described previously (59). The sensitivity was 125
pg/ml (1 U/ml   0.1 ng/ml). TNF was detected using a Quan-
tikine™ M ELISA (R&D Systems) according to the manufac-
turer’s instructions. The sensitivity was  5 pg/ml. TNF-secret-
ing cells were analyzed on a single cell basis by flow cytometric
analysis of intracellular TNF as described previously (60).
Histology and Immunohistochemistry. Tissue for immunohisto-
chemistry was immersed in OCT compound (TissueTek) and
frozen in the vapor phase of liquid N2. 8- m frozen sections
were thawed on gelatinized microscope slides, allowed to dry at
room temperature, and fixed in acetone containing 0.04% (vol/
vol) H2O2 (room temperature, 10 min). Primary and secondary
mAbs were diluted in PBS containing 7.5% (wt/vol) BSA, 10%
(vol/vol) normal mouse serum, and 10 mM NaN3. Primary
mAbs were purified RM4-5 (anti–mouse CD4), purified 53–6.7
(anti–mouse CD8), purified or FITC-conjugated RB6-8C5
(anti-Ly6G, GR-1), purified or FITC-conjugated F4/80 (mouse
macrophages), and the appropriate isotype controls (all BD
PharMingen). Secondary mAbs were peroxidase-conjugated
donkey-anti–rat (Jackson ImmunoResearch Laboratories) or per-
oxidase-conjugated sheep-antifluorescein (Roche). All mAbs
were used at previously determined concentrations (10–50  g/
ml). Peroxidase activity was visualized using diaminobenzidine
(DAB; Sigma-Aldrich). Section were lightly counterstained with
hematoxylin solution (Sigma-Aldrich), dehydrated, and mounted
in Hemode (Fisher Scientific).
Statistical Analysis. The Dunnet procedure for all possible
pairwise contrasts of means with a control mean was performed
as indicated.
Results
IL-18 Is Critical for Resistance to Listeria. To obtain quan-
titative information on the effect of IL-18 on survival to
Listeria, mice were infected with graded doses of the or-
ganism in the presence of a neutralizing mAb to IL-18R
(53). This was compared with an isotype control or anti–
IL-12 mAb, since IL-12 is known to protect from Listeria
(61). For those mice treated with an isotype control mAb
(Fig. 1) or PBS (data not shown), the highest dose of 5  
104 CFUs led to 100% mortality within 4 d, whereas 103
CFUs was sublethal for 100% of these animals. Administra-
tion of anti–IL-18R dramatically increased the susceptibil-
ity to Listeria with 100% of mice now succumbing to as lit-
tle as 103 CFUs by day 4 (Fig. 1 and Table I). In contrast,
anti–IL-12 had no effect on the survival of mice infected
with 103 CFUs (Fig. 1). In fact, 100% mortality was not
observed in anti–IL-12–treated mice until 5 d after they
were infected with  104 CFUs (Fig. 1 and Table I). This
dose was lethal for  50% of isotype control mice (Fig. 1)
and their mean survival was extended to 6 d (Table I) sug-
gesting that IL-12 was playing a protective role in the in-
fection albeit to a lesser extent than IL-18. Impaired sur-
vival was seen to a similar extent whether mice were
treated with anti–IL-18R alone or in conjunction with
anti–IL-12 (Fig. 1 and Table I). Hence these findings indi-
cate that IL-18 may play a more dominant role than IL-12
in survival from a Listeria infection.
Figure 1. Anti–IL-18R treatment
can increase sensitivity to Listeria to
a greater extent than anti–IL-12.
Balb/c mice were injected weekly
with isotype control mAb (GL117),
anti–IL-12, anti–IL-18R, or the
combination of both anticytokine
mAbs before infection with the indi-
cated doses of Listeria as described in
Materials and Methods. Survival was
monitored over the next 8 d and
plotted as a percentage of the total
number of mice per group. 6 mice
per group were assessed and the re-
sults shown were representative of
three experiments.346 Role of IL-18 in Response to Listeria monocytogenes
IL-18–mediated Protection to Listeria Occurs even in the Ab-
sence of IFN- . Since IL-18 synergizes with IL-12 for
IFN-  production by NK and Th1 cells (34, 36) and the
listericidal effects of IL-12 have been shown to be IFN- 
dependent (61), we determined how IL-18 compared with
IL-12 and IFN-  in its ability to resolve a Listeria infection.
Clearance of Listeria from the spleen 3 d after infection was
significantly impaired in those animals pretreated with
anti–IL-18R mAb as compared with isotype control mAb,
whether or not Listeria-infected mice were fully immuno-
competent (Balb/c mice, Fig. 2 A) or lacked T and B cells
(CB17.SCID mice, data not shown). This correlated with
a significant reduction in the levels of IFN-  produced
upon antigen stimulation of spleen cells from the anti–IL-
18R mAb treated group versus the isotype mAb treated
controls (Fig. 2 B). Bacterial clearance was also reduced in
Listeria-infected mice given anti–IL-12 or anti–IFN- 
mAbs as compared with isotype mAb treated control mice
(Fig. 2 A) and as reported previously (16). However, the
bacterial burden remained significantly lower in the anti–
IL-12 or anti–IFN-  mAb treated mice than in the anti–
IL-18R mAb treated mice even though the antigen-spe-
cific IFN-  levels of each group were impaired similarly
(Fig. 2 B). There was no additive effect between anti–IL-
18R and anti–IL-12 since the CFU counts when both
mAbs were given together did not differ from those ob-
tained using the individual mAbs (Fig. 2 A). Taken to-
gether, our observations reveal a critical role for IL-18 in
the clearance of Listeria, which cannot be fully explained
by its effects on IFN-  production.
To rule out the possibility that our findings that IL-18
was more dominant than IFN-  in bacterial clearance was
due to differing mAb efficacies, we also analyzed Balb/
c.IFN- –deficient mice which are more susceptible to Lis-
teria than regular Balb/c mice (Fig. 2 C; reference 21). Bac-
terial clearance was again increased significantly beyond
isotype control levels by administering anti–IL-18R before
infecting these mice (Fig. 2 C).
Table I. Mean Survival Time
Dose of Listeria (CFUs): 103 2   103 5   103 104 5   104
Group
GL117 ND ND ND 6 4
Anti–IL-18R 4 4 3 3 3
Anti–IL-12 ND ND ND 5 4
Anti–IL-12 plus
anti–IL-18R 4 4 3 3 3
Displayed is the mean survival time (in days) of mice from the
experiment described in Fig. 1.
Figure 2. IFN-  cannot completely account for the role of IL-18 in clearance of a Listeria infection.
Mice were injected with isotype control mAb (GL117), anti–IL-18R, anti–IL-12, anti–IFN- , or the
combination of anticytokine mAbs indicated, before infection with the indicated dose of Listeria as de-
scribed in Materials and Methods. (A) The bacterial burden per spleen of Balb/c mice was evaluated 3 d
after infecting with 2   103 CFUs. Each bar represents the mean CFU per group   SD for  5 mice per group. (B) Spleen cells from the same Balb/c
mice were also restimulated ex vivo with 3.9   104 CFU HKLM for 48 h and supernatants analyzed for IFN- . Data are shown for individual mice. (C)
The bacterial burden per spleen of Balb/c and Balb/c.IFN-     mice was evaluated 3 d after infecting with 600 CFUs. Each bar represents the mean
CFU per group   SD for  5 mice per group. Results are representative of greater than three experiments. Statistical analysis was performed using Dun-
nett’s. *P   0.05 versus Balb/c isotype control. **P   0.05 versus Balb/c.IFN-  /  isotype control.347 Neighbors et al.
TNF Contributes to the Protective Effects of IL-18. Since
IL-18 can induce TNF in nonpathogen-driven systems
(62–64) and TNF is critical in eradicating Listeria (17, 18),
we determined how these two cytokines compared in their
ability to clear Listeria. Strikingly, anti–IL-18R had a simi-
lar capacity to anti-TNF in impairing bacterial clearance
(Fig. 3 A). Those mice given either anti–IL-18R or anti-
TNF mAb harbored colonies of Listeria in their spleen 2.5
logs higher than isotype mAb treated control mice by the
third day of infection (Fig. 3 A). In addition, there was no
additive effect between anti–IL-18R and anti-TNF since
the CFU counts when both mAbs were given together did
not differ from those obtained using the individual mAbs
when assessed 2 d after infection and therefore, before the
CFU plateau was reached (Fig. 3 A). Thus, we assessed
bacterial clearance at this earlier time of infection in mice
given mAbs to TNF and/or IFN-  with or without a daily
treatment of rIL-18 to determine whether or not IL-18 re-
quired TNF and/or IFN-  for its protective effects.
The bacterial burden of isotype mAb treated control
mice was indeed significantly reduced by administering
rIL-18 (Fig. 3 B). When rIL-18 was given to mice depleted
of IFN-  the bacterial load was reduced to the level seen
with the isotype controls given rIL-18 (Fig. 3 B) confirm-
ing that this treatment could prevent an otherwise exacer-
bated infection. In contrast, although rIL-18 treatment re-
duced the bacterial burden of mice given mAbs to TNF to
a significant extent, it did not reduce it to the level seen
with either the rIL-18–treated isotype controls or anti–
IFN- –treated mice given rIL-18 (Fig. 3 B). The effects of
rIL-18 on bacterial clearance were similar when mice had
been treated with anti-TNF mAbs alone or in combination
Figure 3. TNF contributes to the protective effects of IL-18. (A) Balb/c mice were injected with the mAbs indicated before infection with 2   103
CFU Listeria and the bacterial burden per spleen was evaluated after 2 or 3 d. (B) Balb/c mice treated with the mAbs indicated were given 2   103 CFU
Listeria and treated daily with either 0.3 ml PBS or an equal volume containing 5  g rIL-18 as indicated. The bacterial burden per spleen was evaluated
after 2 d. Each bar represents the mean CFU per group   SD for  5 mice per group. Results were reproducible in greater than three experiments. Sta-
tistical analysis was performed using Dunnett’s. *P   0.05 versus isotype control plus PBS. **P   0.05 versus isotype control plus rIL-18.
Figure 4. IL-18 induces TNF and NO production
by macrophages from Listeria-infected mice. (A) Ad-
herent peritoneal cells taken from SCID mice 3 d after
infecting with 2   103 CFU Listeria were rested over-
night and stimulated for 48 h with medium, IL-18,
HKLM, or HKLM plus anti–IL-18R at concentrations
detailed in Materials and Methods. The supernatants
were assessed for TNF content by ELISA and data are
represented as the mean   SD of triplicate cultures. (B)
Adherent peritoneal cells from SCID mice left un-
treated or taken 3 d after treating with the mAbs indi-
cated   infecting with 2   103 CFUs Listeria were
stimulated for 16 h with HKLM and supernatants as-
sessed for nitrite content as described in Materials and
Methods. Data are represented as the mean   SD of
duplicate cultures.348 Role of IL-18 in Response to Listeria monocytogenes
with anti–IFN-  mAbs. Overall these findings indicate that
the protective capacity of IL-18 largely required the pro-
duction of TNF and did not appear to require IFN-  in
this early phase of bacterial clearance.
IL-18 Is Required for TNF and NO Production by Listeria-
infected Macrophages. Listeria-infected mice given anti–IL-
18R were not impaired in their antigen-specific produc-
tion of TNF upon restimulation with HKLM in vitro (data
not shown). Therefore, we investigated the macrophage as
an alternative source of TNF in response to IL-18, using
adherent cells from the peritoneal cavity of Listeria-infected
SCID mice. In these cultures the release of TNF was com-
pletely restricted to F4/80  macrophages (data not shown)
and was increased by stimulation with either IL-18 or
HKLM (Fig. 4 A). Moreover, the TNF produced in re-
sponse to HKLM was significantly reduced upon addition
of an anti–IL-18R mAb (Fig. 4 A). Overall these findings
show that IL-18 enhanced the production of TNF by mac-
rophages from Listeria-infected mice. However, no effect
on macrophage TNF regulation ex vivo was observed after
Listeria infection in the presence of anti–IL-18R as com-
pared with isotype control in vivo (data not shown) since
the macrophage produces IL-18 upon stimulation in vitro
thus masking the effects of anti–IL-18R treatment in vivo.
NO forms part of a critical effector pathway involved in
eliminating bacteria from the macrophage (65–67). We
tested if this factor was also influenced by IL-18 using peri-
toneal (or splenic, data not shown) macrophages from
SCID mice. In comparison to cells taken from noninfected
mice, cells from Listeria-infected mice produced far higher
levels of NO upon restimulation with HKLM (Fig. 4 B).
Anti–IL-18R treatment before infection greatly impaired
this response (Fig. 4 B) indicating that IL-18 was also re-
quired for this macrophage effector function. In addition,
NO levels from all groups were lowered by addition of
anti–IL-18R to the cultures themselves (data not shown).
Inhibition of IL-18 Action in Listeria Infection Greatly En-
hances Neutrophilic Microfoci. Livers from Listeria-infected
mice treated with anti–IL-18R showed a dramatically in-
creased GR1 staining for neutrophils, as compared with
controls and this was restricted to microfoci within the tis-
sue (Fig. 5). The frequency of neutrophil-rich microfoci in
mice treated with mAbs to either IL-18R or TNF was sim-
ilar and greater than seen using either anti–IFN-  or anti–
Figure 5. Histological analyses of Listeria-infected mouse livers confirms the dominant role of IL-18 and TNF in primary immune responses to Listeria
infection. Displayed are frozen sections from the livers of Listeria-infected Balb/c mice treated with the mAb combinations indicated and stained with ei-
ther GR1, F4/80, CD4, CD8, or isotype control (data not shown) mAbs as described in Materials and Methods.349 Neighbors et al.
IL-12 mAbs, while the liver appeared normal by day 3 after
infection in control animals (Fig. 5). Hence the frequency
of these microfoci in the liver correlated completely with
the capacity of each mAb to impair bacterial clearance in
the spleen (Fig. 2 A and Fig. 3), but not with IFN-  pro-
duction (Fig. 2 B). F4/80 expression was only found on
Kupffer cells distributed throughout the liver parenchyma,
but not in the microfoci themselves, and was similar in all
groups (Fig. 5), suggesting that additional macrophages had
yet to influx the site at this time point. No CD4 and CD8
staining was found in the control group and only a few
CD4  or CD8  cells were seen at the edge of the micro-
foci of those groups with pathology (Fig. 5).
IL-18 Has a Greater Effect on Th1 Effector Cells after their
Differentiation. Our studies suggest that IL-18 induced
clearance of Listeria in part through its ability to increase
IFN-  production, which is in keeping with its reported
ability to synergize in vitro with IL-12 for the induction of
IFN-  by NK and Th1 cells (34, 68). We assessed the effect
of anti–IL-18R on the development of Th1 cells in vitro by
stimulating CD4  Mel-14hi cells from DO11.10 mice with
HKLM, OVA323–339, and APCs for 1 wk in the presence or
absence of mAbs to IL-18R, IL-12, or TNF. The genera-
tion of Th1 cells was analyzed by measurement of IFN- 
production after restimulating with OVA and APCs. Re-
sults are shown in the absence of HKLM but were identical
whether or not HKLM was present in these secondary re-
call cultures. IL-12 has been previously shown to play a
dominant role in Th1 cell development in contrast to TNF
(19, 20). We now show that anti–IL-18R only slightly re-
duced the optimal development of Th1 cells seen in the ab-
sence of any blocking mAbs (Fig. 6 A). However, as sug-
gested from our earlier studies (34), anti–IL-18R had a
more pronounced effect on IFN-  production during the
recall responses of Th1 cells already developed in the ab-
sence of blocking mAbs for 7 d with HKLM, OVA, and
APCs (Fig. 6 B). However, this was still less effective than
anti–IL-12, which had a more prominent effect at this recall
stage (Fig. 6 B). Anti-TNF had minimal effects not only in
modulating the levels of IFN-  detected from primary de-
velopment but also in recall cultures (Fig. 6, A and B) as
shown previously (20, 69). The role of IL-18 in enhancing
IFN-  production from already differentiated Th1 cells
suggested that this cytokine might be critical for the optimal
maintenance of Th1 responses necessary to generate potent
effector memory cells, which are required for effective bac-
terial clearance of repeated Listeria infections.
IL-18 Is a Dominant Factor in the Memory Effector Response
Induced upon Reinfection with Listeria. To test the role of
IL-18 in memory effector responses to Listeria, mice given
an initial sublethal Listeria infection of 2   103 CFUs were
administered with anticytokine mAbs 27 d later, and then
reinfected with a high dose of 5   104 CFU Listeria on day
28. The animals were assessed for bacterial burden and
IFN-  production after a further 3 d. Isotype-treated con-
trol mice were now able to completely clear this bacterial
infection which is otherwise lethal in a primary response
(Fig. 7 A) and this correlated with high levels of IFN- 
Figure 6. IL-18 has a greater effect on Th1 cells after their differentiation in vitro. Naive CD4  spleen cells sorted from DO11.10 transgenic mice
were set up in primary cultures with HKLM, OVA, and APCs (irradiated spleen cells) for 7 d. (A) Primary T cell cultures were performed in the presence
of medium or mAbs to IL-12, IL-18R, or TNF as described in Materials and Methods. Cells were then restimulated with OVA plus APCs for 48 h and
supernatants harvested to determine IFN-  content. (B) Primary T cell cultures were stimulated with HKLM, OVA, and APCs in the absence of mAbs
for 7 d and then restimulated with HKLM plus OVA plus APCs for 48 h in the presence of medium or mAbs to IL-12, IL-18R, or TNF when superna-
tants were harvested to determine IFN-  content. All possible combinations of Ab were also analyzed in this experiment and their effects on lowering
IFN-  production were found to be additive (results not shown). Results were representative of three experiments and data are represented as the mean  
SD of triplicate cultures.350 Role of IL-18 in Response to Listeria monocytogenes
production upon antigenic stimulation (Fig. 7 B). In con-
trast to the controls, treatment with anti–IL-18R mAb led
to a greatly enhanced bacterial burden, which was signifi-
cantly greater than that observed after treatment with either
anti–IL-12 or anti–IFN-  mAbs (Fig. 7 A). This profound
role of IL-18 in bacterial clearance was not completely at-
tributable to reduction in the levels of IFN- . Specifically,
treatment with anti–IL-18R mAb reduced the levels of
IFN-  to the same extent yet exacerbated the bacterial load
significantly more than either anti–IL-12 or anti–IFN- 
mAbs (Fig. 7, A and B). Indeed, the dominance of anti–IL-
18R over anti–IL-12 was even more dramatic in impairing
recall responses than had been observed in primary re-
sponses to Listeria. The effect of anti–IL-18R mAb on bac-
terial clearance was comparable to that of anti-TNF, al-
though anti-TNF showed no effect on antigen-induced
IFN-  production (Fig. 7). At this challenge dose, there
was no further enhancement in bacterial load using anti–
IL-18R in combination with Abs to TNF, IFN- , or IL-
12 (Fig. 7 A, and data not shown).
In keeping with the similar effects of anti–IL-18R mAb
in primary and secondary Listeria infections, the livers of
mice treated with this mAb before a secondary infection also
contained very high numbers of GR-1  neutrophils within
microfoci (data not shown). This is in keeping with an im-
portant role for IL-18 in the induction of recall responses.
Discussion
This study was performed to determine the role of IL-18
in protective immune responses to the intracellular patho-
gen Listeria. Our findings show that IL-18 provided signifi-
cant protection in both primary and secondary responses to
this pathogen and appeared more potent than either IL-12
or IFN- . Thus, IL-18 has a more extensive role in bacte-
rial clearance than via its ability to induce IFN-  produc-
tion by Th1 and NK cells, since it can exacerbate the bac-
terial load even in IFN- –deficient mice. The main effects
of IL-18 were observed only in the presence of TNF. In-
deed, IL-18 induced macrophage production of TNF as
well as NO, which is critical for its antimicrobial effects.
Overall, our findings show that IL-18 plays a very impor-
tant role in cell-mediated immunity via its effects on both
the innate and adaptive immune response, which appear
important for both primary and secondary challenge with
this intracellular pathogen. Thus, IL-18 may prove to be
beneficial when used as part of an antimicrobial treatment
or when targeted as a therapeutic strategy for those disor-
ders associated with Th1 inflammatory responses.
Our data show that IL-18 plays a dominant role in the
clearance of Listeria in a manner not fully attributable to the
induction of IFN- . Evidence for this came from the fol-
lowing findings. First, the bacterial load and mortality was
higher in the absence of IL-18 than in the absence of IL-
12, while the production of IFN-  was reduced similarly in
each case. Secondly, IL-18, but not IL-12, was dominant
over IFN-  in controlling the bacterial load after infection.
Furthermore, the  infection was greatly exacerbated by
anti–IL-18R mAb even in IFN-  /  mice. Finally, IL-18
operated independently of IFN-  to reduce the bacterial
load early in infection. Although these findings are consis-
tent with the IFN- –dependent role of IL-12 in protection
to a primary challenge with Listeria (16) they suggest an ad-
ditional role for IL-18. We had originally published find-
ings describing the mechanism by which IL-18 induced
IFN-  production by Th1 cells in concert with IL-12 (34).
Moreover, many studies now suggest that the ability of IL-
18 to enhance cell-mediated Th1-type responses is mainly
via the upregulation of the IL-12 receptor (70, 71). Our
present findings, showing that IL-18 has effects over and
above the induction of IFN- , demonstrate its more global
role in immune responses than had originally been sug-
gested. That IFN-  levels remained detectable after anti–
IL-18R mAb treatment also indicated that the responsive
cells were not being depleted by this mAb.
We show that IL-18 and TNF display a similar capacity
to protect mice from Listeria and that the protection medi-
ated by IL-18 can only partially overcome the ability of
Figure 7. A critical role for IL-18 in memory recall responses and sub-
sequent clearance of a repeat Listeria infection. Balb/c mice were infected
with 2   103 CFU Listeria and 27 d later groups were treated with the in-
dicated mAbs and then reinfected with 5   104 CFU Listeria on day 28.
After a further 3 d the bacterial burden per spleen (A) and IFN-  produc-
tion by spleen cells upon restimulation with HKLM antigen for 48 h (B)
were evaluated as described for Fig. 2. Results were representative of
three experiments. Statistical analysis was performed using Dunnett’s. *P  
0.05 versus isotype control.351 Neighbors et al.
anti-TNF to enhance the bacterial load, thereby demon-
strating that IL-18 mediates protection to a large extent
through TNF action in vivo. Since we were unable to
demonstrate a requirement for IL-18 in the TNF produced
by in vitro cultures designed to stimulate T and NK cells
from Listeria-infected mice we investigated the macrophage
as an alternative IL-18–dependent source of TNF. Indeed,
we found that TNF production by F4/80  peritoneal mac-
rophages was induced by IL-18 after a Listeria infection, in
keeping with previous findings in nonpathogen-driven sys-
tems (62–64). Moreover, our ability to show that the TNF
produced in response to HKLM was IL-18–dependent
provided further evidence for the TNF-inducing properties
of IL-18 in response to Listeria. Hence we conclude that
the role of IL-18 in responses to Listeria encompasses the
induction of TNF production by macrophages and IFN- 
production by antigen-specific T cells and NK cells.
Our findings showing that macrophages were triggered
by IL-18 to secrete TNF in response to Listeria led us to
speculate that other properties of the macrophage may also
be IL-18 dependent. We confirm here that IL-18 is re-
quired for the macrophage’s subsequent release of NO in
response to a Listeria infection in vivo. Since NO produc-
tion is a key mediator of the macrophage's listericidal effects
(65–67), this may be a major mechanism to explain the
profound influence of IL-18 on bacterial clearance.
We also show that upon neutralization of IL-18, Listeria
elicited a massive neutrophil influx to the liver with forma-
tion of multiple microfoci. This pathology was comparable
to that seen in the absence of TNF with fewer and smaller
microfoci observed in the absence of either IL-12 or IFN- .
Hence, the situation in the liver correlated with the rel-
ative capacity for bacterial clearance from the spleen in
these situations. It has been shown that a “spillover” of Lis-
teria from the granuloma to neutrophilic microabscesses oc-
curs in SCID mice chronically infected with Listeria and
depleted of IFN-  or TNF (72). In our hands, a lack of IL-
18 receptor signaling resulted in a similar outcome but in
this case in immunocompetent mice, reflecting an inability
to clear the organism and a disruption in the equilibrium
between the macrophage-rich granulomas and the neutro-
philic microabscesses.
Here we show for the first time that in addition to its
protective role in primary immunity to Listeria, IL-18 is as
important in memory effector responses to reinfection with
Listeria. Since IL-18 was required for optimal levels of IFN- 
it may represent the missing element which has been postu-
lated to act in combination with IL-12 for maximal IFN- 
recall responses to Listeria (28). Hence, one role for IL-18
may be to induce optimal Th1 memory effector cell re-
sponses to repeat infections with Listeria. However, in our
hands IL-18 appeared to have a more extensive role in bac-
terial clearance than via its effects on IFN- . Indeed IL-18
was as potent as TNF in bacterial clearance. Effective recall
responses to Listeria are known to require TNF (27, 29) but
its mechanism of induction and subsequent effects remain
to be clearly defined in a recall response to Listeria. The ex-
tent to which IL-18 operates via TNF and/or other addi-
tional mechanisms in a secondary infection also remains to
be determined. As these findings were reminiscent of those
observed during a primary immune response to Listeria and
indeed the histology was also similar, it seems possible that
similar mechanisms may operate to eradicate intracellular
pathogens during primary and memory effector responses,
with IL-18 playing a dominant role at both stages.
It is also possible that IL-18 influences other responses
and/or cell types invoked by a Listeria infection. IL-18 can
augment the cytotoxic activity of CD8  T cells (73) and
this cell subset is an essential component of the host defense
to Listeria (40). The rapid mortality of Listeria-infected mice
given anti–IL-18R showed that IL-18 was important for
controlling bacterial expansion at an early stage in the in-
fection. Indeed we found that mice treated with anti–IL-
18R did not survive beyond days 3–4 (Fig. 1) even after in-
fecting with only 100 CFU Listeria (data not shown). Since
a primary CTL response to Listeria is not detectable until
after this time (74, 75) we were unable to determine how
its induction was affected by anti–IL-18R mAb treatment.
Memory effector CTLs on the other hand are invoked
more quickly to Listeria (74, 75), and we show here that
IL-18 is also required for an effective recall response to sec-
ondary challenge with Listeria. However, we could find no
impairment of the antigen-specific CTL responses during a
secondary challenge in Listeria-immune mice treated with
anti–IL-18R before reinfection (data not shown). There-
fore, we can conclude that IL-18 is not required for the cy-
totoxic effector function of memory CTLs induced by a
secondary infection with Listeria. However, the bacterial
load is very high (Fig. 7 A) when Listeria-immune mice are
given anti–IL-18R mAbs before reinfection suggesting that
the CTL activity may be insufficient for host resistance in
the absence of effective innate immunity. Moreover, the
possibility still exists that IL-18 is required for the develop-
ment of memory CTLs. This will be difficult to assess since
mice will not survive treatment with anti–IL-18R mAbs
during a primary infection to allow the development of
memory CTL responses to Listeria.
IL-18 has been shown to be important for organism
clearance in a number of acute pathogenic infections. IL-
18 /  mice were impaired in their capacity to eliminate
Leishmania major (46) and Shigella (47). Moreover, anti–IL-
18 treatment exacerbated the bacterial burden after infec-
tion with Salmonella (48) or Yersinia (44), while IL-18 pro-
tein treatment reduced titers of herpes simplex virus type 1
(45) and lowered pock formation after a Vaccinia virus in-
fection (49). Only this latter study suggested an IFN- –
independent protective role for IL-18 by showing that IL-18
treatment improved symptoms even in mice infected with
Vaccinia virus and depleted of IFN- . The extent of IFN-
 –independent IL-18–mediated protection had not, to our
knowledge, been investigated in bacterial infections.
Moreover, only the role of IL-18 in the acute response to
an initial infection had been focused on in the existing lit-
erature, in contrast to our study demonstrating a role for
IL-18 in both primary and recall responses to Listeria infec-
tions.352 Role of IL-18 in Response to Listeria monocytogenes
In conclusion, our study shows that IL-18 plays a pro-
found role in protective cell-mediated immune responses
to an intracellular pathogen, which extend beyond its
known effects on the induction of IFN-  by NK and T
cells, to the induction of TNF  and NO  production by
macrophages. For these reasons we believe that our data
have important therapeutic implications for the use of IL-
18 to induce appropriate immune responses during vacci-
nation or to eradicate chronic infections arising as a result
of immunosuppression. Conversely, it is known that such
responses can also be pathology-inducing in autoimmune
and inflammatory disorders and indeed IL-18 has been im-
plicated in the development of several autoimmune diseases
(76–80). Therefore, our data would predict that antagoniz-
ing the global effects of IL-18 might have more impact on
the treatment of such diseases than the current strategies of
TNF, IL-12, or IFN-  antagonism. Our novel finding that
IL-18 is necessary for a recall cell-mediated immune re-
sponse further supports the potential for using IL-18 antag-
onists in preexisting inflammatory pathologies.
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